Department of Blood Transfusion, The First People's Hospital of Yunnan Province, Yunnan Province, Kunming, China.
Department of Hematology, The First People's Hospital of Yunnan Province, Yunnan Province, Kunming, China.
Mol Genet Genomic Med. 2020 Jul;8(7):e1231. doi: 10.1002/mgg3.1231. Epub 2020 Apr 29.
Pharmacogenomics plays a crucial role in individualized therapy, but the variant information of pharmacogenomics in the Dai population is limited. We therefore aimed to screen very important pharmacogenetic (VIP) in the Dai population and compared differences between Dai and other 25 populations.
In this study, we genotyped 73 VIP variants from the PharmGKB and compared genotype distribution of variants in Dai with other 25 populations by χ2 test. To assess the genetic relationship among 26 populations, we performed the structure analysis. In addition, pair-wise F-statistics (Fst) was calculated to measure the population differentiation.
We found 12, 10, 13, 17, 11, 39, 46, 46, 45, 43, 49, 46, 46, 46, 49, 45, 41, 42, 48, 53, 45, 50, 50, 51, 47, and 50 significantly different variants in Dai compared with other 25 populations. Genetic structure analysis showed Dai had close relationships with CDX (Chinese Dai in Xishuangbanna), CHB (Han Chinese in Beijing), JPT (Japanese in Tokyo), and KHV (Kinh in Ho Chi Minh City, Vietnam). Moreover, Dai is the most similar to KHV according to Fst analysis.
Our study complement the pharmacogenomics information of Dai population from Yunnan province and provide a theoretical basis for personalized medicine.
药物基因组学在个体化治疗中起着至关重要的作用，但傣族人群的药物基因组学变异信息有限。因此，我们旨在筛选傣族人群中的非常重要的药物遗传学（VIP）变异，并比较傣族与其他 25 个人群之间的差异。
本研究对 73 个 VIP 变异进行基因分型，并通过卡方检验比较傣族与其他 25 个人群的变异基因型分布。为评估 26 个人群之间的遗传关系，我们进行了结构分析。此外，还计算了两两群体间 F 统计量（Fst）以衡量群体分化。
我们发现与其他 25 个人群相比，傣族人群中存在 12、10、13、17、11、39、46、46、45、43、49、46、46、46、49、45、41、42、48、53、45、50、50、51、47 和 50 个显著不同的变异。遗传结构分析表明，傣族与 CDX（西双版纳傣族）、CHB（北京汉族）、JPT（东京日本人）和 KHV（胡志明市京族人，越南）关系密切。此外，根据 Fst 分析，傣族与 KHV 最为相似。
本研究补充了来自云南省傣族人群的药物基因组学信息，为个体化医学提供了理论依据。
